Kedrion Biopharma announces enrollment of first patient in CARES10 trial

This article was originally published here

CARES10 is a United States/Canada-based open-label, prospective, multi-center phase 3 clinical study to assess efficacy, safety and pharmacokinetics of a 10 percent intravenous immunoglobulin in the treatment of

The post Kedrion Biopharma announces enrollment of first patient in CARES10 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply